CL King Maintains 'Strong Buy' Rating on Quidel (QDEL), Raises PT to $22
More News related to QDEL
- Quidel (QDEL) Reports Strong Q3 Results
- Quidel Corp. (QDEL) halted; Reporting EPS of $0.50
- Quidel Reports Third Quarter 2009 Results
- Quidel Announces Launch of Their MicroVue(R) C5a EIA Kit for Research Use Only
- Quidel (QDEL) and BioHelix to Jointly Develop and Commercialize In Vitro Molecular and Diagnostic Tests
More News related to Analyst Comments
- Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
- Bove Says US Banking System, Dollar to Benefit from Dubai Crisis
- Broadpoint.AmTech Says Solar Inventory Getting Healthier into Year-end
- UBS Maintains a Neutral rating on American Eagle Outfitters (AEO); Lowers Estimates Through 2011
- Barclays Reiterates an 'Overweight' on Deere (DE); Adjusts Estimates & PT
CL King maintains a 'Strong Buy' rating on Quidel (Nasdaq: QDEL), raises price target from $18 to $22.
To see more analyst ratings on QDEL Click Here.
Quidel Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of point-of-care (POC) diagnostic solutions for infectious diseases, and reproductive and women's health.
Related Categories
Analyst CommentsStocks Mentioned
-0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
